Integration of caveolin-mediated cytosolic delivery and enzyme-responsive releasing of squalenoyl nanoparticles enhance the anti-cancer efficacy of chidamide in pancreatic cancer

Chen, Junyan; Chen, Kaidi; Xue, Shuai; Cheng, Xiao; Qi, Yuwei; Wang, Hangjie; Li, Wei; Cheng, Guilin; Xiong, Yang; Mu, Chaofeng; Gu, Mancang

doi:10.1016/j.ijpharm.2024.124072

International Journal of Pharmaceutics

2024

DOI: 10.1016/j.ijpharm.2024.124072

|View full text |Cite

Integration of caveolin-mediated cytosolic delivery and enzyme-responsive releasing of squalenoyl nanoparticles enhance the anti-cancer efficacy of chidamide in pancreatic cancer

Junyan Chen,

Kaidi Chen,

Shuai Xue

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy

Wang,

Bi,

et al. 2025

Biomaterials

View full text Add to dashboard Cite

Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy

Wang,

Bi,

et al. 2025

Biomaterials

View full text Add to dashboard Cite

Recent Advances in the Development and Utilization of Nanoparticles for the Management of Malignant Solid Tumors

Chavan,

Bhosale,

Thorat

et al. 2024

Cureus

View full text Add to dashboard Cite

The purpose of nanotechnology-based drug delivery systems or novel drug delivery systems is to improve the effectiveness of therapy, and their promising properties have led to their increasing significance in the management of cancer. The researchers have primarily focused on designing novel nanocarriers, like nanoparticles (NPs), that can effectively deliver drugs to target cells and respond specifically to conditions particular to cancer. Whether passive or active targeting, these nanocarriers can deliver therapeutic cargoes to the tumor site to release the drug from the drug delivery systems. The purpose of this study is to provide recent scientific literature and key findings to researchers as well as the scientific community from the medical and pharmaceutical domains by reporting current advancements in the development of NPs for the treatment of different malignant solid tumors, such as colorectal, pancreatic, prostate, and cervical cancer.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Integration of caveolin-mediated cytosolic delivery and enzyme-responsive releasing of squalenoyl nanoparticles enhance the anti-cancer efficacy of chidamide in pancreatic cancer

Cited by 2 publications

References 48 publications

Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy

Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy

Recent Advances in the Development and Utilization of Nanoparticles for the Management of Malignant Solid Tumors

Contact Info

Product

Resources

About